Items Tagged ‘Lenvima’

January 25, 2018

Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential treatment of patients with advanced renal cell carcinoma (RCC). About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are […]

View full entry

Tags: immunotherapy, keytruda, lenvatinib, Lenvima, News, pembrolizumab, Precision Cancer Medicine, Renal Cancer, renal cell cancer


May 28, 2015

Lenvima®

By

Class: Biological Therapy Generic Name: Lenvatinib Trade Name: Lenvima® For which conditions is this drug approved? Lenvima is approved to treat people with a type of thyroid cancer called differentiated thyroid cancer (DTC) when the disease can no longer be treated with radioactive iodine and is progressing. It is also indicated for patients with advanced renal […]

View full entry

Tags: Biological Therapy, differentiated thyroid cancer, Drug Dictionary, L, lenvatinib, Lenvima, Thyroid Cancer


May 28, 2015

Lenvatinib

By

Class: Biological Therapy Generic Name: Lenvatinib Trade Name: Lenvima® For which conditions is this drug approved? Lenvima is approved to treat people with a type of thyroid cancer called differentiated thyroid cancer (DTC) when the disease can no longer be treated with radioactive iodine and is progressing. It is also indicated for patients with advanced renal […]

View full entry

Tags: Biological Therapy, differentiated thyroid cancer, Drug Dictionary, L, lenvatinib, Lenvima, Thyroid Cancer